Home Antibody All anti-CHUK antibodies
Anti-CHUK Antibody EPR464
Also for CHUK (NM_001278)
|A synthetic peptide corresponding to residues in human IKK alpha was used as an immunogen.|
||Tissue culture supernatant
||0.5~1.0 mg/ml (Lot Dependent)
||WB: 1:1000 - 1:10000; IP: 1:10 - 1:100; IHC-P: 1:100 - 1:250; ICC: 1:50 - 1:100
|Does not react with Mouse, Rat. Is unsuitable for Flow Cyt.|
|PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05% (Protein A or G Sepharose)
|Is unsuitable for Flow Cyt.
|Homo sapiens conserved helix-loop-helix ubiquitous kinase (CHUK)|
|IKBKA; IKK-alpha; IKK1; IKKA; NFKBIKA; TCF16|
|IKK alpha (I-Kappa-B kinase alpha) is a member of the IKK complex that is composed of IKK alpha, IKK beta, IKK gamma and IKAP (1-2). Phosphorylation of I-Kappa-B on a serine residue by the IKK complex frees NF-kB from I-Kappa-B and marks it for degradation via ubiquination. Activation of NFKB by TNF requires phosphorylation of IKK alpha at threonine 23 and serine 176 by AKT1 and NIK, respectively (3). It has been demonstrated that IKK alpha can accumulate in the nucleus after cytokine exposure (4). In the nucleus, IKK alpha interacts with CREB-binding protein in conjunction with RELA to be recruited to the NF-kappa-B-responsive promoters in order to mediate cytokine-induced phosphorylation and subsequent acetylation of specific residues in histone H3 (5).|
MAPK signaling pathway
Toll-like receptor signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - IKK alpha antibody [EPR464]; All lanes : Anti-IKK alpha antibody [EPR464] at 1/1000 dilution.Lane 1 : Jurkat cell lysate.Lane 2 : HeLa cell lysate.Lane 3 : HepG2 cell lysate.Lane 4 : Daudi cell lysate.Lysates/proteins at 10 µg per lane.Predicted band size : 85 kDa.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - IKK alpha antibody [EPR464]; ab109749, at 1/100 dilution, staining IKK alpha in paraffin-embedded Human breast tissue by Immunohistochemistry.